A Bull Market Continues To Unfold On ImmunityBio Inc. (NASDAQ: IBRX), As It Continued To Fall -35.20% In Year-To-Date – Marketing Sentinel
Home  »  Science   »  A Bull Market Continues To Unfold On ImmunityBio I...

A Bull Market Continues To Unfold On ImmunityBio Inc. (NASDAQ: IBRX), As It Continued To Fall -35.20% In Year-To-Date

During the last session, ImmunityBio Inc. (NASDAQ:IBRX)’s traded shares were 1.4 million, with the beta value of the company hitting 1.90. At the end of the trading day, the stock’s price was $3.94, reflecting an intraday gain of 10.06% or $0.36. The 52-week high for the IBRX share is $15.65, that puts it down -297.21 from that peak though still a striking 34.01% gain since the share price plummeted to a 52-week low of $2.60. The company’s market capitalization is $1.46B, and the average intraday trading volume over the past 10 days was 3.13 million shares, and the average trade volume was 1.99 million shares over the past three months.

ImmunityBio Inc. (NASDAQ:IBRX) trade information

ImmunityBio Inc. (IBRX) registered a 10.06% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 10.06% in intraday trading to $3.94 this Thursday, 06/23/22, hitting a weekly high. The stock’s 5-day price performance is 22.74%, and it has moved by 3.41% in 30 days. Based on these gigs, the overall price performance for the year is -71.92%. The short interest in ImmunityBio Inc. (NASDAQ:IBRX) is 17.23 million shares and it means that shorts have 11.48 day(s) to cover.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


ImmunityBio Inc. (IBRX) estimates and forecasts

In the rating firms’ projections, revenue will decrease -89.30% compared to the previous financial year.

Revenue for the current quarter is expected to be $20k as predicted by 1 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to $20k by the end of Sep 2022.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 9.60%. While earnings are projected to return -51.40% in 2022, the next five years will return -1.70% per annum.

IBRX Dividends

ImmunityBio Inc. is due to release its next quarterly earnings in July. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

ImmunityBio Inc. (NASDAQ:IBRX)’s Major holders

ImmunityBio Inc. insiders own 79.64% of total outstanding shares while institutional holders control 8.93%, with the float percentage being 43.86%. Vanguard Group, Inc. (The) is the largest shareholder of the company, while 206 institutions own stock in it. As of Dec 30, 2021, the company held over 7.14 million shares (or 1.79% of all shares), a total value of $43.4 million in shares.

The next largest institutional holding, with 6.22 million shares, is of State Street Corporation’s that is approximately 1.56% of outstanding shares. At the market price on Dec 30, 2021, these shares were valued at $37.79 million.

Also, the Mutual Funds coming in first place with the largest holdings of ImmunityBio Inc. (IBRX) shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. Data provided on Jan 30, 2022 indicates that SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF owns about 5.35 million shares. This amounts to just over 1.34 percent of the company’s overall shares, with a $31.13 million market value. The same data shows that the other fund manager holds slightly less at 2.23 million, or about 0.56% of the stock, which is worth about $13.57 million.

Leave a Comment

Your email address will not be published.

On Key

Related Posts